A Phase 2 efficacy study to evaluate VL-2397 in the treatment of patients with invasive aspergillosis.
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2016
At a glance
- Drugs VL 2397
- Indications Aspergillosis
- Focus Therapeutic Use
- 18 Nov 2016 New trial record
- 03 Nov 2016 According a Vical media release, company is working with FDA on design of this trial.